Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CPH NASDAQ:CRON TSE:GUD NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHCipher PharmaceuticalsC$12.33-4.5%C$12.77C$8.38▼C$19.69C$221.36M1.229,185 shs23,960 shsCRONCronos Group$2.01-2.0%$1.99$1.60▼$2.54$775.22M1.031.37 million shs1.78 million shsGUDKnight TherapeuticsC$6.05-2.6%C$5.91C$5.09▼C$6.45C$611.96M0.566,777 shs164,416 shsTLRYTilray Brands$0.62+1.6%$0.46$0.35▼$2.15$615.27M1.8231.26 million shs28.80 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHCipher Pharmaceuticals-4.49%-4.57%-4.57%+3.53%+48.02%CRONCronos Group-1.95%-3.83%+5.24%+13.56%-17.96%GUDKnight Therapeutics-2.58%-1.31%+1.85%+6.33%+5.40%TLRYTilray Brands+1.64%+7.03%+62.09%+38.07%-67.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPHCipher Pharmaceuticals1.5782 of 5 stars2.40.00.00.02.11.71.3CRONCronos Group2.0409 of 5 stars0.04.00.00.02.60.02.5GUDKnight Therapeutics1.0562 of 5 stars2.80.00.00.00.01.70.6TLRYTilray Brands1.8731 of 5 stars3.11.00.00.03.10.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHCipher Pharmaceuticals 2.75Moderate BuyC$14.7519.63% UpsideCRONCronos Group 0.00N/AN/AN/AGUDKnight Therapeutics 3.50Strong BuyC$7.1518.18% UpsideTLRYTilray Brands 2.25Hold$1.92208.49% UpsideCurrent Analyst Ratings BreakdownLatest CPH, CRON, GUD, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ BuyC$6.50(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHCipher PharmaceuticalsC$19.03M11.63C$3.49 per share3.53C$3.96 per share3.11CRONCronos Group$124.59M6.22$0.00 per share4,405.57$2.90 per share0.69GUDKnight TherapeuticsC$348.70M1.75C$1.57 per share3.85C$7.65 per share0.79TLRYTilray Brands$210.48M2.97N/AN/A$4.14 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHCipher PharmaceuticalsC$11.41MC$0.9113.62∞N/A59.92%17.93%7.90%N/ACRONCronos Group$41.08M$0.1315.4667.00N/A39.69%-0.07%-0.07%8/6/2025 (Estimated)GUDKnight Therapeutics-C$30.73M-C$0.30N/A∞N/A-8.81%-4.04%0.51%N/ATLRYTilray Brands-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%7/28/2025 (Estimated)Latest CPH, CRON, GUD, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CRONCronos Group-$0.02N/AN/AN/AN/AN/A7/28/2025Q4 2025TLRYTilray Brands-$0.03N/AN/AN/A$250.41 millionN/A5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPHCipher PharmaceuticalsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHCipher Pharmaceuticals41.222.002.67CRONCronos GroupN/A27.8026.75GUDKnight Therapeutics7.523.361.79TLRYTilray Brands0.122.621.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHCipher Pharmaceuticals1.38%CRONCronos Group8.71%GUDKnight Therapeutics12.58%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCPHCipher Pharmaceuticals42.00%CRONCronos Group7.30%GUDKnight Therapeutics45.62%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHCipher Pharmaceuticals517.95 millionN/ANot OptionableCRONCronos Group450385.68 million357.53 millionOptionableGUDKnight Therapeutics725101.15 millionN/ANot OptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableCPH, CRON, GUD, and TLRY HeadlinesRecent News About These CompaniesTop Canadian Cannabis Picks for U.S. Market Expansion in 2025July 19 at 10:00 AM | marijuanastocks.comMMarketBeat Week in Review – 07/14 - 07/18 (TLRY)...July 19 at 7:00 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Up 3.2% - Here's What HappenedJuly 18 at 1:42 PM | marketbeat.comTilray Brands, Inc. (TLRY) Beats Stock Market Upswing: What Investors Need to KnowJuly 17 at 7:00 PM | zacks.comTilray Brands (NASDAQ:TLRY) Trading Up 4% - Should You Buy?July 17 at 6:17 PM | marketbeat.comTilray (TLRY) Stock Is Up, What You Need To KnowJuly 16 at 3:15 PM | msn.comTilray Brands (NASDAQ:TLRY) Shares Up 4% - What's Next?July 16 at 1:29 PM | marketbeat.comTilray Brands (NasdaqGS:TLRY) Soars 44% In Last MonthJuly 15, 2025 | finance.yahoo.comTilray (TLRY) Shares Skyrocket, What You Need To KnowJuly 15, 2025 | msn.comTilray Brands (NASDAQ:TLRY) Trading Down 6.2% - What's Next?July 15, 2025 | marketbeat.comTilray Brands stock price is surging: time to buy or sell?July 15, 2025 | invezz.comITilray Brands stock price is surging: time to buy or sell?July 15, 2025 | invezz.comIUp Around 40% in Just the Past Month, Could This Red-Hot Growth Stock Rally Even Higher?July 15, 2025 | fool.comTilray Shares Blazing: What's Behind the 55% Rally This Month?...July 14, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Up 7% - Here's What HappenedJuly 14, 2025 | marketbeat.comTilray Brands, Inc. (TLRY) Declines More Than Market: Some Information ...July 13, 2025 | finance.yahoo.comCannabis Stocks To Follow Today - July 13thJuly 13, 2025 | marketbeat.comPromising Cannabis Stocks To Follow Now - July 12thJuly 12, 2025 | marketbeat.comTilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for InvestorsJuly 11, 2025 | zacks.comTop Cannabis Stocks To Watch Today - July 11thJuly 11, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Down 5.4% - Should You Sell?July 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Tech Stocks Poised for Explosive EPS Growth in 2025By Gabriel Osorio-Mazilli | July 8, 2025View 3 Tech Stocks Poised for Explosive EPS Growth in 2025Micron Insiders Sell But Investors Should Buy, Buy, BuyBy Thomas Hughes | July 7, 2025View Micron Insiders Sell But Investors Should Buy, Buy, BuyTilray Shares Blazing: What's Behind the 55% Rally This Month?By Nathan Reiff | July 14, 2025View Tilray Shares Blazing: What's Behind the 55% Rally This Month?Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingBy Thomas Hughes | June 26, 2025View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are ComingMicron’s Big Q3 Drives Applied Materials’ Bullish OutlookBy Leo Miller | July 3, 2025View Micron’s Big Q3 Drives Applied Materials’ Bullish OutlookCPH, CRON, GUD, and TLRY Company DescriptionsCipher Pharmaceuticals TSE:CPHC$12.33 -0.58 (-4.49%) As of 07/18/2025 04:00 PM EasternCipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.Cronos Group NASDAQ:CRON$2.01 -0.04 (-1.95%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.00 -0.01 (-0.75%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Knight Therapeutics TSE:GUDC$6.05 -0.16 (-2.58%) As of 07/18/2025 04:00 PM EasternKnight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.Tilray Brands NASDAQ:TLRY$0.62 +0.01 (+1.64%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.63 +0.01 (+1.72%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.